Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Week in review: How Trump's policies moved stocks » 07:32
08/08/20
08/08
07:32
08/08/20
07:32
TCEHY

Tencent

$0.00 /

+ (+0.00%)

, MSFT

Microsoft

$212.45 /

-3.87 (-1.79%)

, AZN

AstraZeneca

$55.40 /

-0.8 (-1.42%)

, BMY

Bristol-Myers

$61.03 /

-0.27 (-0.44%)

, LLY

Eli Lilly

$152.89 /

+0.01 (+0.01%)

, GSK

GlaxoSmithKline

$40.79 /

-0.185 (-0.45%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, KODK

Eastman Kodak

$14.88 /

-1.195 (-7.43%)

, AA

Alcoa

$14.67 /

-0.22 (-1.48%)

, CENX

Century Aluminum

$10.53 /

-0.06 (-0.57%)

, KALU

Kaiser Aluminum

$66.81 /

+0.49 (+0.74%)

, ARNC

Arconic

$19.94 /

-0.395 (-1.94%)

, FB

Facebook

$268.52 /

+3.295 (+1.24%)

, TWTR

Twitter

$37.14 /

-0.55 (-1.46%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
07/14/20 Citi
Tencent price target raised to HK$649 from HK$541 at Citi
07/08/20 Mizuho
Tencent price target raised to HK$475 from HK$410 at Mizuho
MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

08/07/20 DA Davidson
Datadog price target raised to $80 from $52 at DA Davidson
08/05/20 Morgan Stanley
Morgan Stanley says TikTok US operations could be 'compelling' fit for Microsoft
08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

07/16/20 B. Riley FBR
Alcoa price target raised to $11 from $9 at B. Riley FBR
06/16/20
Fly Intel: Top five analyst downgrades
06/16/20 Deutsche Bank
Alcoa downgraded to Hold with $10 price target at Deutsche Bank
06/15/20 Deutsche Bank
Alcoa downgraded to Hold from Buy at Deutsche Bank
CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

06/25/20 BMO Capital
Century Aluminum downgraded to Market Perform from Outperform at BMO Capital
06/09/20 B. Riley FBR
B. Riley FBR downgrades Contura Energy after liquidity stress test
03/24/20 B. Riley FBR
Century Aluminum downgraded to Neutral from Buy at B. Riley FBR
12/20/19 B. Riley FBR
Alcoa price target lowered to $25 from $28 at B. Riley FBR
KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

01/16/20 Benchmark
Kaiser Aluminum initiated with a Hold at Benchmark
08/08/19 Goldman Sachs
Kaiser Aluminum upgraded to Neutral from Sell at Goldman Sachs
ARNC Arconic
$19.94 /

-0.395 (-1.94%)

05/20/20
Fly Intel: Top five analyst initiations
05/20/20 Credit Suisse
Arconic initiated with an Outperform at Credit Suisse
04/01/20 Cowen
Howmet Aerospace price target lowered to $17 from $23 at Cowen
03/20/20 Barclays
Arconic downgraded to Equal Weight from Overweight at Barclays
FB Facebook
$268.52 /

+3.295 (+1.24%)

08/05/20 HSBC
HSBC bumps up Facebook target to $195, maintains Reduce rating
08/04/20 Argus
Facebook price target raised to $300 from $270 at Argus
08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
08/03/20 DA Davidson
Pinterest price target raised to $28 from $19 at DA Davidson
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

Friday
Syndicate
Gilead files automatic mixed securities shelf  16:04
08/07/20
08/07
16:04
08/07/20
16:04
GILD

Gilead

$69.31 /

+0.51 (+0.74%)

 
ShowHide Related Items >><<
GILD Gilead
$69.31 /

+0.51 (+0.74%)

GILD Gilead
$69.31 /

+0.51 (+0.74%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
GILD Gilead
$69.31 /

+0.51 (+0.74%)

GILD Gilead
$69.31 /

+0.51 (+0.74%)

GILD Gilead
$69.31 /

+0.51 (+0.74%)

GILD Gilead
$69.31 /

+0.51 (+0.74%)

Hot Stocks
PTC wins FDA approval of spinal muscular atrophy treatment Evrysdi » 13:58
08/07/20
08/07
13:58
08/07/20
13:58
PTCT

PTC Therapeutics

$50.33 /

+3.31 (+7.04%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

PTC Therapeutics (PTCT)…

PTC Therapeutics (PTCT) announced that the Food and Drug Administration has approved Evrysdi, the first at-home, orally administered treatment for spinal muscular atrophy in adults and children two months and older. Evrysdi will be available in the United States within two weeks for direct delivery to patients' homes through Accredo Health Group, an Express Scripts specialty pharmacy, PTC noted. Evrysdi will be marketed in the United States by Genentech, a unit of Roche Group (RHHBY). Outside the United States, Roche holds global commercialization rights to risdiplam. Shares of PTC Therapeutics halted for trade up 7% to $50.35.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
06/09/20 Citi
PTC Therapeutics pipeline not fully appreciated, says Citi
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

  • 18
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

Hot Stocks
Roche announces FDA approval of Evrysdi for Spinal Muscular Atrophy treatment » 13:50
08/07/20
08/07
13:50
08/07/20
13:50
PTCT

PTC Therapeutics

$50.19 /

+3.17 (+6.74%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, ESRX

Express Scripts

$92.49 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Evrysdi, or risdiplam, for treatment of spinal muscular atrophy, or SMA, in adults and children 2 months of age and older. A liquid medicine, Evrysdi is administered daily at home by mouth or feeding tube. Evrysdi is designed to treat SMA by increasing production of the survival of motor neuron protein, which is found throughout the body and is critical for maintaining healthy motor neurons and movement, the company said. Genentech leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics (PTCT). Evrysdi will be available in the United States within two weeks for direct delivery to patients' homes through Accredo Health Group, an Express Scripts (ESRX) specialty pharmacy.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

ESRX Express Scripts
$92.49 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
06/09/20 Citi
PTC Therapeutics pipeline not fully appreciated, says Citi
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
ESRX Express Scripts
$92.49 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

  • 18
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

Hot Stocks
Roche announces FDA approval of Evrysdi for Spinal Muscular Atrophy treatment  13:48
08/07/20
08/07
13:48
08/07/20
13:48
PTCT

PTC Therapeutics

$50.10 /

+3.08 (+6.55%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
06/09/20 Citi
PTC Therapeutics pipeline not fully appreciated, says Citi
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

  • 18
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

Hot Stocks
Pfizer announces agreement with Gilead to manufacture remdesivir » 08:05
08/07/20
08/07
08:05
08/07/20
08:05
PFE

Pfizer

$38.27 /

-0.18 (-0.47%)

, GILD

Gilead

$68.80 /

-0.19 (-0.28%)

Pfizer (PFE) said in a…

Pfizer (PFE) said in a release, "Pfizer announced a multi-year agreement with Gilead Sciences (GILD) to manufacture and supply Gilead's investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer's McPherson, Kansas facility to manufacture and supply remdesivir for Gilead. In March, Pfizer launched a five-point plan, which called on all members of the innovation ecosystem - from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions - to commit to work together in addressing the dire COVID-19 crisis."

ShowHide Related Items >><<
PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

PFE Pfizer
$38.27 /

-0.18 (-0.47%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
GILD Gilead
$68.80 /

-0.19 (-0.28%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

PFE Pfizer
$38.27 /

-0.18 (-0.47%)

GILD Gilead
$68.80 /

-0.19 (-0.28%)

Thursday
On The Fly
Fly Intel: Wall Street's top stories for Thursday » 17:44
08/06/20
08/06
17:44
08/06/20
17:44
WDC

Western Digital

$37.30 /

-7.15 (-16.09%)

, BMY

Bristol-Myers

$61.30 /

+1.61 (+2.70%)

, BHC

Bausch Health

$20.14 /

+0.69 (+3.55%)

, FB

Facebook

$265.23 /

+16.045 (+6.44%)

, RKT

Rocket Companies

$21.62 /

+ (+0.00%)

, DNLI

Denali Therapeutics

$31.64 /

+8.39 (+36.09%)

, OTRK

Ontrak

$56.77 /

+17.41 (+44.23%)

, CVNA

Carvana

$223.07 /

+48.65 (+27.89%)

, MAXR

Maxar Technologies

$25.01 /

+4.27 (+20.59%)

, SONO

Sonos

$14.27 /

-3.22 (-18.41%)

, OSUR

OraSure

$13.09 /

-6.51 (-33.21%)

, INSG

Inseego

$12.21 /

-2.55 (-17.28%)

, AMRS

Amyris

$4.04 /

-0.915 (-18.48%)

The major averages were…

Open Full Text

ShowHide Related Items >><<
WDC Western Digital
$37.30 /

-7.15 (-16.09%)

SONO Sonos
$14.27 /

-3.22 (-18.41%)

OSUR OraSure
$13.09 /

-6.51 (-33.21%)

MAXR Maxar Technologies
$25.01 /

+4.27 (+20.59%)

INSG Inseego
$12.21 /

-2.55 (-17.28%)

FB Facebook
$265.23 /

+16.045 (+6.44%)

DNLI Denali Therapeutics
$31.64 /

+8.39 (+36.09%)

CVNA Carvana
$223.07 /

+48.65 (+27.89%)

BMY Bristol-Myers
$61.30 /

+1.61 (+2.70%)

BHC Bausch Health
$20.14 /

+0.69 (+3.55%)

AMRS Amyris
$4.04 /

-0.915 (-18.48%)

WDC Western Digital
$37.30 /

-7.15 (-16.09%)

08/06/20
Fly Intel: Top five analyst downgrades
08/06/20 Craig-Hallum
Western Digital downgraded to Hold at Craig-Hallum
08/06/20 Baird
Western Digital price target lowered to $50 from $75 at Baird
08/06/20 Summit Insights
Western Digital downgraded to Hold from Buy at Summit Insights
BMY Bristol-Myers
$61.30 /

+1.61 (+2.70%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
BHC Bausch Health
$20.14 /

+0.69 (+3.55%)

08/07/20 Barclays
Bausch Health price target raised to $28 from $25 at Barclays
06/17/20 H.C. Wainwright
Bausch Health price target raised to $64 from $50 at H.C. Wainwright
06/03/20 Jefferies
Duobrii could become a key revenue driver for Bausch Health, says Jefferies
04/24/20
Fly Intel: Top five analyst initiations
FB Facebook
$265.23 /

+16.045 (+6.44%)

08/05/20 HSBC
HSBC bumps up Facebook target to $195, maintains Reduce rating
08/04/20 Argus
Facebook price target raised to $300 from $270 at Argus
08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
08/03/20 DA Davidson
Pinterest price target raised to $28 from $19 at DA Davidson
RKT Rocket Companies
$21.62 /

+ (+0.00%)

DNLI Denali Therapeutics
$31.64 /

+8.39 (+36.09%)

08/06/20 Goldman Sachs
Denali's LRRK2 program complementary to Biogen's PD pipeline, says Goldman Sachs
08/06/20 Wells Fargo
Biogen 'doubling down on LRRK2' via deal with Denali, says Wells Fargo
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
03/13/20 Evercore ISI
Denali Therapeutics upgraded to Outperform from In Line at Evercore ISI
OTRK Ontrak
$56.77 /

+17.41 (+44.23%)

08/06/20 Canaccord
Ontrak price target raised to $70 from $36 at Canaccord
08/06/20 RBC Capital
Ontrak price target raised to $50 from $35 at RBC Capital
07/16/20 Cowen
Ontrak risk/reward attractive, Cowen starts at Outperform
07/16/20 Cowen
Ontrak initiated with an Outperform at Cowen
CVNA Carvana
$223.07 /

+48.65 (+27.89%)

08/07/20 BofA
Carvana downgraded to Neutral from Buy at BofA
08/07/20 BofA
Carvana downgraded to Neutral from Buy at BofA
08/06/20 Wells Fargo
Carvana price target raised to $200 from $175 at Wells Fargo
08/06/20 Wedbush
Carvana price target raised to $170 from $125 at Wedbush
MAXR Maxar Technologies
$25.01 /

+4.27 (+20.59%)

08/06/20 TD Securities
Maxar Technologies upgraded to Buy from Speculative Buy at TD Securities
06/24/20 JPMorgan
Maxar Technologies price target raised to $20 from $16 at JPMorgan
01/15/20 Credit Suisse
Maxar Technologies upgraded to Neutral from Underperform at Credit Suisse
01/08/20 JPMorgan
Maxar Technologies price target raised to $25 from $15 at JPMorgan
SONO Sonos
$14.27 /

-3.22 (-18.41%)

07/29/20 Raymond James
Sonos double downgraded to Market Perform at Raymond James
07/29/20 Raymond James
Sonos downgraded to Market Perform from Strong Buy at Raymond James
07/23/20 MScience
Sonos recently launched products driving record channel sales, says MScience
07/14/20 RBC Capital
Sonos price target raised to $19 from $12 at RBC Capital
OSUR OraSure
$13.09 /

-6.51 (-33.21%)

08/07/20 Raymond James
OraSure upgraded to Outperform from Market Perform at Raymond James
06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
INSG Inseego
$12.21 /

-2.55 (-17.28%)

08/06/20 Lake Street
Inseego price target raised to $17 from $13 at Lake Street
08/06/20 Roth Capital
Inseego downgraded to Neutral on valuation at Roth Capital
08/06/20 Northland
Inseego downgraded to Market Perform on valuation at Northland
AMRS Amyris
$4.04 /

-0.915 (-18.48%)

12/12/19
Fly Intel: Top five analyst initiations
12/12/19 Oppenheimer
Amyris initiated with an Outperform at Oppenheimer with $8 price target
12/11/19 Oppenheimer
Amyris initiated with an Outperform at Oppenheimer
WDC Western Digital
$37.30 /

-7.15 (-16.09%)

SONO Sonos
$14.27 /

-3.22 (-18.41%)

OTRK Ontrak
$56.77 /

+17.41 (+44.23%)

OSUR OraSure
$13.09 /

-6.51 (-33.21%)

MAXR Maxar Technologies
$25.01 /

+4.27 (+20.59%)

INSG Inseego
$12.21 /

-2.55 (-17.28%)

FB Facebook
$265.23 /

+16.045 (+6.44%)

DNLI Denali Therapeutics
$31.64 /

+8.39 (+36.09%)

CVNA Carvana
$223.07 /

+48.65 (+27.89%)

BMY Bristol-Myers
$61.30 /

+1.61 (+2.70%)

BHC Bausch Health
$20.14 /

+0.69 (+3.55%)

AMRS Amyris
$4.04 /

-0.915 (-18.48%)

  • 06
    Aug
  • 18
    Jun
  • 03
    Jun
  • 19
    May
  • 29
    Jan
WDC Western Digital
$37.30 /

-7.15 (-16.09%)

SONO Sonos
$14.27 /

-3.22 (-18.41%)

RKT Rocket Companies
$21.62 /

+ (+0.00%)

FB Facebook
$265.23 /

+16.045 (+6.44%)

CVNA Carvana
$223.07 /

+48.65 (+27.89%)

BMY Bristol-Myers
$61.30 /

+1.61 (+2.70%)

WDC Western Digital
$37.30 /

-7.15 (-16.09%)

SONO Sonos
$14.27 /

-3.22 (-18.41%)

OTRK Ontrak
$56.77 /

+17.41 (+44.23%)

OSUR OraSure
$13.09 /

-6.51 (-33.21%)

MAXR Maxar Technologies
$25.01 /

+4.27 (+20.59%)

INSG Inseego
$12.21 /

-2.55 (-17.28%)

FB Facebook
$265.23 /

+16.045 (+6.44%)

DNLI Denali Therapeutics
$31.64 /

+8.39 (+36.09%)

CVNA Carvana
$223.07 /

+48.65 (+27.89%)

BMY Bristol-Myers
$61.30 /

+1.61 (+2.70%)

BHC Bausch Health
$20.14 /

+0.69 (+3.55%)

AMRS Amyris
$4.04 /

-0.915 (-18.48%)

WDC Western Digital
$37.30 /

-7.15 (-16.09%)

SONO Sonos
$14.27 /

-3.22 (-18.41%)

OTRK Ontrak
$56.77 /

+17.41 (+44.23%)

MAXR Maxar Technologies
$25.01 /

+4.27 (+20.59%)

INSG Inseego
$12.21 /

-2.55 (-17.28%)

FB Facebook
$265.23 /

+16.045 (+6.44%)

CVNA Carvana
$223.07 /

+48.65 (+27.89%)

BMY Bristol-Myers
$61.30 /

+1.61 (+2.70%)

BHC Bausch Health
$20.14 /

+0.69 (+3.55%)

AMRS Amyris
$4.04 /

-0.915 (-18.48%)

Hot Stocks
ViiV announces FDA approval of expanded indication for Dovato » 17:30
08/06/20
08/06
17:30
08/06/20
17:30
GSK

GlaxoSmithKline

$40.98 /

-0.235 (-0.57%)

ViiV Healthcare announced…

ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Dovato (dolutegravir/lamivudine) as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral (ARV) regimen in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to the individual components of Dovato.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$40.98 /

-0.235 (-0.57%)

GSK GlaxoSmithKline
$40.98 /

-0.235 (-0.57%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
GSK GlaxoSmithKline
$40.98 /

-0.235 (-0.57%)

GSK GlaxoSmithKline
$40.98 /

-0.235 (-0.57%)

GSK GlaxoSmithKline
$40.98 /

-0.235 (-0.57%)

GSK GlaxoSmithKline
$40.98 /

-0.235 (-0.57%)

Hot Stocks
Editas Medicine regains full global rights to ocular medicines » 16:04
08/06/20
08/06
16:04
08/06/20
16:04
EDIT

Editas Medicine

$36.72 /

+4.36 (+13.47%)

, ABBV

AbbVie

$92.61 /

-0.62 (-0.67%)

Editas Medicine (EDIT)…

Editas Medicine (EDIT) announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10, which were previously shared within a strategic research and development alliance with Allergan, which has since been acquired by AbbVie (ABBV). Editas Medicine and AbbVie have terminated the original agreement and entered into a new agreement.

ShowHide Related Items >><<
EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

06/18/20 Truist
Editas Medicine initiated with a Buy at SunTrust
02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

08/05/20 Benchmark
Voyager 'break up' with AbbVie has no impact on valuation, says Benchmark
07/31/20 Piper Sandler
Piper reiterates $110 target on AbbVie after 'impressive beat'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

  • 24
    Jun
EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

Hot Stocks
Genentech says Phase III IMpassion131 study did not meet primary endpoint » 16:01
08/06/20
08/06
16:01
08/06/20
16:01
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced that the Phase III IMpassion131 study, evaluating Tecentriq (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoint of OS and data were immature at time of analysis. OS follow-up is planned to continue until final analysis. Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.